Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 2/2017

01-04-2017 | ORIGINAL ARTICLE

3’UTR AU-Rich Elements (AREs) and the RNA-Binding Protein Tristetraprolin (TTP) Are Not Required for the LPS-Mediated Destabilization of Phospholipase-Cβ-2 mRNA in Murine Macrophages

Authors: Smita Shukla, Genie Elson, Perry J. Blackshear, Carol S. Lutz, S. Joseph Leibovich

Published in: Inflammation | Issue 2/2017

Login to get access

ABSTRACT

We have shown previously that bacterial lipopolysaccharide (LPS)-mediated suppression of phospholipase-Cβ-2 (PLCβ-2) expression is involved in M1 (inflammatory) to M2-like (wound healing) phenotypic switching of macrophages triggered by adenosine. This suppression is mediated post-transcriptionally by destabilization of PLCβ-2 mRNA (messenger ribonucleic acid). To investigate the mechanism of this LPS-mediated destabilization, we examined the roles of RNA-binding agents including microRNAs and RNA-binding proteins that are involved in regulating stability of mRNAs encoding growth factors, inflammatory mediators, and proto-oncogenes. Adenylate and uridylate (AU)-rich elements (AREs) in 3’UTRs are specific recognition sites for RNA-binding proteins including tristetraprolin (TTP), HuR, and AUF1 and for microRNAs that are involved in regulating mRNA stability. In this study, we investigated the role of TTP and AREs in regulating PLCβ-2 mRNA stability. The 3’UTR of the PLCβ-2 gene was inserted into the pLightswitch luciferase reporter plasmid and transfected into RAW264.7 cells. LPS suppressed luciferase expression from this reporter. Luciferase expression from mutant 3’UTR constructs lacking AREs was similarly downregulated, suggesting that these regions are not required for LPS-mediated suppression of PLCβ-2. TTP was rapidly upregulated in both primary murine macrophages and RAW264.7 cells in response to LPS. Suppression of PLCβ-2 by LPS was examined using macrophages from mice lacking TTP (TTP−/−). LPS suppressed PLCβ-2 expression to the same extent in wild type (WT) and TTP−/− macrophages. Also, the rate of decay of PLCβ-2 mRNA in LPS-treated macrophages following transcriptional blockade was similar in WT and TTP−/− macrophages, clearly indicating that TTP is not involved in LPS-mediated destabilization of PLCβ-2 mRNA in macrophages.
Literature
1.
Grinberg, S., G. Hasko, D. Wu, and S.J. Leibovich. 2009. Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. The American Journal of Pathology 175: 2439–53.CrossRefPubMedPubMedCentral
2.
Goerdt, S., O. Politz, K. Schledzewski, R. Birk, A. Gratchev, P. Guillot, N. Hakiy, C.D. Klemke, E. Dippel, V. Kodelja, and C.E. Orfanos. 1999. Alternative versus classical activation of macrophages. Pathobiology 67: 222–6.CrossRefPubMed
3.
4.
Mantovani, A., B. Bottazzi, S. Sozzani, G. Peri, P. Allavena, Q.G. Dong, A. Vecchi, and F. Colotta. 1993. Cytokine regulation of tumour-associated macrophages. Research in Immunology 144: 280–3.CrossRefPubMed
5.
Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 23: 549–55.CrossRefPubMed
6.
7.
Tietzel, I., and D.M. Mosser. 2002. The modulation of macrophage activation by tyrosine phosphorylation. Frontiers in Bioscience 7: d1494–502.CrossRefPubMed
8.
9.
Cros, J., N. Cagnard, K. Woollard, N. Patey, S.Y. Zhang, B. Senechal, A. Puel, S.K. Biswas, D. Moshous, C. Picard, J.P. Jais, D. D’Cruz, J.L. Casanova, C. Trouillet, and F. Geissmann. 2010. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33: 375–86.CrossRefPubMedPubMedCentral
10.
Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71–82.CrossRefPubMed
11.
Leibovich, S.J., J.F. Chen, G. Pinhal-Enfield, P.C. Belem, G. Elson, A. Rosania, M. Ramanathan, C. Montesinos, M. Jacobson, M.A. Schwarzschild, J.S. Fink, and B. Cronstein. 2002. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. The American Journal of Pathology 160: 2231–44.CrossRefPubMedPubMedCentral
12.
Biswas, S.K., A. Sica, and C.E. Lewis. 2008. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. The Journal of Immunology 180: 2011–7.CrossRefPubMed
13.
Varin, A., S. Mukhopadhyay, G. Herbein, and S. Gordon. 2010. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood 115: 353–62.CrossRefPubMedPubMedCentral
14.
Martinez, F.O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annual Review of Immunology 27: 451–83.CrossRefPubMed
15.
Pinhal-Enfield, G., M. Ramanathan, G. Hasko, S.N. Vogel, A.L. Salzman, G.J. Boons, and S.J. Leibovich. 2003. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7 and 9 and adenosine A2A receptors. The American Journal of Pathology 163: 711–21.CrossRefPubMedPubMedCentral
16.
Csoka, B., Z.H. Nemeth, L. Virag, P. Gergely, S.J. Leibovich, P. Pacher, C.X. Sun, M.R. Blackburn, E.S. Vizi, E.A. Deitch, and G. Hasko. 2007. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110: 2685–95.CrossRefPubMedPubMedCentral
17.
Csoka, B., Z. Selmeczy, B. Koscso, Z.H. Nemeth, P. Pacher, P.J. Murray, D. Kepka-Lenhart, S.M. Morris Jr., W.C. Gause, S.J. Leibovich, and G. Hasko. 2012. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. The FASEB Journal 26: 376–86.CrossRefPubMedPubMedCentral
18.
Elson, G., M. Eisenberg, C. Garg, S. Outram, C.J. Ferrante, G. Hasko, and S.J. Leibovich. 2013. Induction of murine adenosine A(2A) receptor expression by LPS: analysis of the 5′ upstream promoter. Genes and Immunity 14: 147–153.CrossRefPubMed
19.
20.
Ferrante, C.J., G. Pinhal-Enfield, G. Elson, B.N. Cronstein, G. Hasko, S. Outram, and S.J. Leibovich. 2013. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation 36: 921–31.CrossRefPubMedPubMedCentral
21.
Lai, W.S., D.J. Stumpo, and P.J. Blackshear. 1990. Rapid insulin-stimulated accumulation of an mRNA encoding a proline-rich protein. The Journal of Biological Chemistry 265: 16556–63.PubMed
22.
Lai, W.S., E. Carballo, J.R. Strum, E.A. Kennington, R.S. Phillips, and P.J. Blackshear. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Molecular and Cellular Biology 19: 4311–23.CrossRefPubMedPubMedCentral
23.
Lai, W.S., E. Carballo, J.M. Thorn, E.A. Kennington, and P.J. Blackshear. 2000. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. The Journal of Biological Chemistry 275: 17827–37.CrossRefPubMed
24.
Brooks, S.A., and P.J. Blackshear. 1829. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochimica et Biophysica Acta 2013: 666–79.
25.
Sanduja, S., F.F. Blanco, L.E. Young, V. Kaza, and D.A. Dixon. 2012. The role of tristetraprolin in cancer and inflammation. Frontiers in Bioscience 17: 174–88.CrossRef
26.
DuBois, R.N., M.W. McLane, K. Ryder, L.F. Lau, and D. Nathans. 1990. A growth factor-inducible nuclear protein with a novel cysteine/histidine repetitive sequence. The Journal of Biological Chemistry 265: 19185–91.PubMed
27.
Ma, Q., and H.R. Herschman. 1991. A corrected sequence for the predicted protein from the mitogen-inducible TIS11 primary response gene. Oncogene 6: 1277–8.PubMed
28.
Varnum, B.C., R.W. Lim, V.P. Sukhatme, and H.R. Herschman. 1989. Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene 4: 119–20.PubMed
29.
Taylor, G.A., E. Carballo, D.M. Lee, W.S. Lai, M.J. Thompson, D.D. Patel, D.I. Schenkman, G.S. Gilkeson, H.E. Broxmeyer, B.F. Haynes, and P.J. Blackshear. 1996. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4: 445–54.CrossRefPubMed
30.
Tchen, C.R., M. Brook, J. Saklatvala, and A.R. Clark. 2004. The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself. The Journal of Biological Chemistry 279: 32393–400.CrossRefPubMed
31.
Chen, Y.L., Y.W. Jiang, Y.L. Su, S.C. Lee, M.S. Chang, and C.J. Chang. 2013. Transcriptional regulation of tristetraprolin by NF-kappaB signaling in LPS-stimulated macrophages. Molecular Biology Reports 40: 2867–77.CrossRefPubMed
32.
Cao, H., J.S. Tuttle, and P.J. Blackshear. 2004. Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein. The Journal of Biological Chemistry 279: 21489–99.CrossRefPubMedPubMedCentral
33.
34.
Perez-Ortin, J.E., P. Alepuz, S. Chavez, and M. Choder. 2013. Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression. Journal of Molecular Biology 425: 3750–75.CrossRefPubMed
35.
36.
Shen, Z.J., and J.S. Malter. 2015. Regulation of AU-Rich Element RNA Binding Proteins by Phosphorylation and the Prolyl Isomerase Pin1. Biomolecules 5: 412–34.CrossRefPubMedPubMedCentral
37.
Houseley, J., J. LaCava, and D. Tollervey. 2006. RNA-quality control by the exosome. Nature Reviews. Molecular Cell Biology 7: 529–39.CrossRefPubMed
38.
Liu, H., N.D. Rodgers, X. Jiao, and M. Kiledjian. 2002. The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases. The EMBO Journal 21: 4699–708.CrossRefPubMedPubMedCentral
39.
Moser, M.J., W.R. Holley, A. Chatterjee, and I.S. Mian. 1997. The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains. Nucleic Acids Research 25: 5110–8.CrossRefPubMedPubMedCentral
40.
Fenger-Gron, M., C. Fillman, B. Norrild, and J. Lykke-Andersen. 2005. Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping. Molecular Cell 20: 905–15.CrossRefPubMed
41.
42.
Yu, J.H., W.H. Yang, T. Gulick, K.D. Bloch, and D.B. Bloch. 2005. Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body. RNA 11: 1795–802.CrossRefPubMedPubMedCentral
43.
Badis, G., C. Saveanu, M. Fromont-Racine, and A. Jacquier. 2004. Targeted mRNA degradation by deadenylation-independent decapping. Molecular Cell 15: 5–15.CrossRefPubMed
44.
Muhlrad, D., and R. Parker. 2005. The yeast EDC1 mRNA undergoes deadenylation-independent decapping stimulated by Not2p, Not4p, and Not5p. The EMBO Journal 24: 1033–45.CrossRefPubMedPubMedCentral
45.
Gatfield, D., and E. Izaurralde. 2004. Nonsense-mediated messenger RNA decay is initiated by endonucleolytic cleavage in Drosophila. Nature 429: 575–8.CrossRefPubMed
46.
Stevens, A., Y. Wang, K. Bremer, J. Zhang, R. Hoepfner, M. Antoniou, D.R. Schoenberg, and L.E. Maquat. 2002. Beta -Globin mRNA decay in erythroid cells: UG site-preferred endonucleolytic cleavage that is augmented by a premature termination codon. Proceedings of the National Academy of Sciences of the United States of America 99: 12741–6.CrossRefPubMedPubMedCentral
47.
Stoecklin, G., M. Lu, B. Rattenbacher, and C. Moroni. 2003. A constitutive decay element promotes tumor necrosis factor alpha mRNA degradation via an AU-rich element-independent pathway. Molecular and Cellular Biology 23: 3506–15.CrossRefPubMedPubMedCentral
48.
49.
Pierrat, B., F. Lacroute, and R. Losson. 1993. The 5′ untranslated region of the PPR1 regulatory gene dictates rapid mRNA decay in yeast. Gene 131: 43–51.CrossRefPubMed
50.
Herrick, D., and A. Jacobson. 1992. A coding region segment is necessary, but not sufficient for rapid decay of the HIS3 mRNA in yeast. Gene 114: 35–41.CrossRefPubMed
51.
Khabar, K.S. 2005. The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. Journal of Interferon and Cytokine Research 25: 1–10.CrossRefPubMed
52.
Carballo, E., W.S. Lai, and P.J. Blackshear. 1998. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001–5.CrossRefPubMed
53.
Carballo, E., W.S. Lai, and P.J. Blackshear. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95: 1891–9.PubMed
54.
Douni, E., K. Akassoglou, L. Alexopoulou, S. Georgopoulos, S. Haralambous, S. Hill, G. Kassiotis, D. Kontoyiannis, M. Pasparakis, D. Plows, L. Probert, and G. Kollias. 1995. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. Journal of Inflammation 47: 27–38.PubMed
55.
Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. The EMBO Journal 10: 4025–31.PubMedPubMedCentral
56.
Phillips, K., N. Kedersha, L. Shen, P.J. Blackshear, and P. Anderson. 2004. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proceedings of the National Academy of Sciences of the United States of America 101: 2011–6.CrossRefPubMedPubMedCentral
57.
Suswam, E., Y. Li, X. Zhang, G.Y. Gillespie, X. Li, J.J. Shacka, L. Lu, L. Zheng, and P.H. King. 2008. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Research 68: 674–82.CrossRefPubMed
58.
Brennan, S.E., Y. Kuwano, N. Alkharouf, P.J. Blackshear, M. Gorospe, and G.M. Wilson. 2009. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Research 69: 5168–76.CrossRefPubMedPubMedCentral
59.
Gebeshuber, C.A., and K. Zatloukal. 2009. Martinez J: miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Reports 10: 400–5.CrossRefPubMedPubMedCentral
60.
Carrick, D.M., and P.J. Blackshear. 2007. Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Archives of Biochemistry and Biophysics 462: 278–85.CrossRefPubMed
61.
Sanduja, S., V. Kaza, and D.A. Dixon. 2009. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging 1: 803–17.CrossRefPubMedPubMedCentral
Metadata
Title
3’UTR AU-Rich Elements (AREs) and the RNA-Binding Protein Tristetraprolin (TTP) Are Not Required for the LPS-Mediated Destabilization of Phospholipase-Cβ-2 mRNA in Murine Macrophages
Authors
Smita Shukla
Genie Elson
Perry J. Blackshear
Carol S. Lutz
S. Joseph Leibovich
Publication date
01-04-2017
Publisher
Springer US
Published in
Inflammation / Issue 2/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0511-y

Other articles of this Issue 2/2017

Inflammation 2/2017 Go to the issue

REVIEW

MicroRNA-155: a Novel Armamentarium Against Inflammatory Diseases

ORIGINAL ARTICLE

Physio-pharmacological Investigations About the Anti-inflammatory and Antinociceptive Efficacy of (+)-Limonene Epoxide

ORIGINAL ARTICLE

Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin

ORIGINAL ARTICLE

Exosomes from iPSCs Delivering siRNA Attenuate Intracellular Adhesion Molecule-1 Expression and Neutrophils Adhesion in Pulmonary Microvascular Endothelial Cells

ORIGINAL ARTICLE

The Anti-inflammatory Activities of Two Major Withanolides from Physalis minima Via Acting on NF-κB, STAT3, and HO-1 in LPS-Stimulated RAW264.7 Cells

ORIGINAL ARTICLE

Bone Morphogenetic Protein-Modulator BMPER Regulates Endothelial Barrier Function
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits